Last reviewed · How we verify
NCT04811352
Drug Abuse During the COVID-19 Pandemic.
trial in Substance Abuse in 200 participants. Completed in 1 June 2021.
1 May 2021
Quick facts
| Lead sponsor | Instituto Mexicano del Seguro Social |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 1 March 2021 |
| Primary completion | 1 May 2021 |
| Estimated completion | 1 June 2021 |
| Sites | 1 location across Mexico |
Conditions studied
- Substance Abuse — all drugs for Substance Abuse →
- Stress, Psychological — all drugs for Stress, Psychological →
Sponsor
Instituto Mexicano del Seguro Social — full company profile →
Who can join
18 and older, any sex, with Substance Abuse or Stress, Psychological. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The pandemic we live through has put various sectors of the medical system and its tributaries to the test. The accumulation of external and internal stress has been completely correlated with the predisposition to psycho-emotional problems and, in turn, to drug use as an immature response for ego protection. That is why the economic, social, and psychological evaluation can help understand the current situation about drug abuse and how to help patients afflicted by it. The added stress of personal problems, work alterations, daily life in a pandemic, economic and varied responsibilities, and the understanding of the pandemic have predisposed and amplified the use of drugs to reduce emotional distress perceived by individuals. The hypothesis of this study is that the increment of stress and a lack of preparation for the pandemic are associated with increased drug abuse.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Substance Use and Psychological Distress in Mexican Adults during COVID-19 Pandemic: A Cross-Sectional Study.
Ibarrola-Peña JC, Cueto-Valadez TA, Chejfec-Ciociano JM, Cifuentes-Andrade LR, et al · · 2022 · cited 3× · PMID 36613036 · DOI 10.3390/ijerph20010716
Verify or expand the search:
- PubMed search for NCT04811352
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Substance Abuse
Currently open trials in the same condition.
- NCT06627764 — SER Familia: A Family-Based Intervention Addressing Syndemic Conditions Among Latino Immigrant Families · NA · recruiting
- NCT06899308 — Health Surveillance at Constructor University Bremen (CUB) and Among HAW-Hamburg Employees · recruiting
- NCT06880705 — The Trans-Led Care Study · NA · recruiting
- NCT06852170 — Data2Action Oregon Project: Supporting Data-driven Decision-Making for Substance Use Services, Policy, and Overdose Prev · NA · recruiting
- NCT05776316 — Harm Reduction Services · NA · recruiting
Other Instituto Mexicano del Seguro Social trials
Trials by the same sponsor.
- NCT07536009 — "Effectiveness of a Telerehabilitation Program Versus a Conventional Rehabilitation Program in Patients With Subacromial · NA · not yet recruiting
- NCT06632184 — Peritoneal Lavage Using Saline or Saline With Ondansetron for Pain Control After Laparoscopic Cholecystectomy · Phase 4 · active not recruiting
- NCT07073846 — Effect of Lidocaine-Dexmedetomidine on Pain, Inflammation, and Oxidative Stress After Bariatric Surgery. · Phase 4 · recruiting
- NCT07406971 — Safety of Transmucosal Capsaicin Sphenopalatine Ganglion Stimulation in Acute Ischemic Stroke · Phase 2 · recruiting
- NCT07134504 — Primary Prostatic Lymphoma on a 66 Year-old Male in Mexico. · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04811352 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Instituto Mexicano del Seguro Social
- Last refreshed: 2 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04811352.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing